<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36482422</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>08</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy.</ArticleTitle><Pagination><StartPage>80</StartPage><MedlinePgn>80</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">80</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-022-00585-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Cytoplasmic mislocalization and aggregation of TAR DNA-binding protein-43 (TDP-43) is a hallmark of the amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD) disease spectrum, causing both nuclear loss-of-function and cytoplasmic toxic gain-of-function phenotypes. While TDP-43 proteinopathy has been associated with defects in nucleocytoplasmic transport, this process is still poorly understood. Here we study the role of karyopherin-&#x3b2;1 (KPNB1) and other nuclear import receptors in regulating TDP-43 pathology.</AbstractText><AbstractText Label="METHODS">We used immunostaining, immunoprecipitation, biochemical and toxicity assays in cell lines, primary neuron and organotypic mouse brain slice cultures, to determine the impact of KPNB1 on the solubility, localization, and toxicity of pathological TDP-43 constructs. Postmortem patient brain and spinal cord tissue was stained to assess KPNB1 colocalization with TDP-43 inclusions. Turbidity assays were employed to study the dissolution and prevention of aggregation of recombinant TDP-43 fibrils in vitro. Fly models of TDP-43 proteinopathy were used to determine the effect of KPNB1 on their neurodegenerative phenotype in vivo.</AbstractText><AbstractText Label="RESULTS">We discovered that several members of the nuclear import receptor protein family can reduce the formation of pathological TDP-43 aggregates. Using KPNB1 as a model, we found that its activity depends on the prion-like C-terminal region of TDP-43, which mediates the co-aggregation with phenylalanine and glycine-rich nucleoporins (FG-Nups) such as Nup62. KPNB1 is recruited into these co-aggregates where it acts as a molecular chaperone that reverses aberrant phase transition of Nup62 and TDP-43. These findings are supported by the discovery that Nup62 and KPNB1 are also sequestered into pathological TDP-43 aggregates in ALS/FTD postmortem CNS tissue, and by the identification of the fly ortholog of KPNB1 as a strong protective modifier in Drosophila models of TDP-43 proteinopathy. Our results show that KPNB1 can rescue all hallmarks of TDP-43 pathology, by restoring its solubility and nuclear localization, and reducing neurodegeneration in cellular and animal models of ALS/FTD.</AbstractText><AbstractText Label="CONCLUSION">Our findings suggest a novel NLS-independent mechanism where, analogous to its canonical role in dissolving the diffusion barrier formed by FG-Nups in the nuclear pore, KPNB1 is recruited into TDP-43/FG-Nup co-aggregates present in TDP-43 proteinopathies and therapeutically reverses their deleterious phase transition and mislocalization, mitigating neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khalil</LastName><ForeName>Bilal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chhangani</LastName><ForeName>Deepak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wren</LastName><ForeName>Melissa C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Courtney L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mayo Clinic Graduate School of Biomedical Sciences, Neuroscience Track, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jannifer H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mayo Clinic Graduate School of Biomedical Sciences, Neuroscience Track, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xingli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puttinger</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Gael</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morderer</LastName><ForeName>Dmytro</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Junli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feilin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Chun Kim</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Graduate School of Biostudies, Kyoto University, Yoshida-konoe, Sakyo-ku, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jingjiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Department, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Ching-Chieh</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Biology, Stanford University, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croft</LastName><ForeName>Cara L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute at University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gleixner</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LiveLikeLou Center for ALS Research, University of Pittsburgh Brain Institute, Pittsburgh, PA, 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>LiveLikeLou Center for ALS Research, University of Pittsburgh Brain Institute, Pittsburgh, PA, 15261, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshimura</LastName><ForeName>Shige H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Graduate School of Biostudies, Kyoto University, Yoshida-konoe, Sakyo-ku, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barmada</LastName><ForeName>Sami J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rincon-Limas</LastName><ForeName>Diego E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Neurology, McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Genetics Institute, University of Florida, Gainesville, FL, 32610, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossoll</LastName><ForeName>Wilfried</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-9622-541X</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, 32224, USA. rossoll.wilfried@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54NS123743</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01NS084974</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG064940</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS113943</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS133676</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG059871</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG072931</GrantID><Acronym>RG</Acronym><Agency>CSR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS127187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS105756</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 NS110960</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS097542</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS105756</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG077771</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AG064940</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG048607</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS117461</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG068581</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35NS097273</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG068581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS127187</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS100055</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS098379</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS086749</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS096647</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG076122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33NS110960</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG077771</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072931</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG062677</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028861">Nuclear Pore Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C424166">KPNB1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021581" MajorTopicYN="N">Active Transport, Cell Nucleus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D028861" MajorTopicYN="N">Nuclear Pore Complex Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aggregation</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Drosophila</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Importin</Keyword><Keyword MajorTopicYN="N">Nuclear pore</Keyword><Keyword MajorTopicYN="N">Nucleocytoplasmic transport</Keyword><Keyword MajorTopicYN="N">Prion-like domain</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare they have no financial competing interests. BK and WR are co-inventors on a patent relating to the content of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>9</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36482422</ArticleId><ArticleId IdType="pmc">PMC9733332</ArticleId><ArticleId IdType="doi">10.1186/s13024-022-00585-1</ArticleId><ArticleId IdType="pii">10.1186/s13024-022-00585-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A, Bharathi V, Sivalingam V, Girdhar A, Patel BK. Molecular mechanisms of TDP-43 Misfolding and pathology in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:25. doi: 10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527. doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Bassell GJ, Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum Mol Genet. 2012;21:3703&#x2013;3718. doi: 10.1093/hmg/dds205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds205</ArticleId><ArticleId IdType="pmc">PMC3406762</ArticleId><ArticleId IdType="pubmed">22641816</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, Zennaro E, Fallini C, Weber M, Sommacal A, Buratti E, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111:1051&#x2013;1061. doi: 10.1111/j.1471-4159.2009.06383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06383.x</ArticleId><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil B, Morderer D, Price PL, Liu F, Rossoll W. mRNP assembly, axonal transport, and local translation in neurodegenerative diseases. Brain Res. 2018;1693:75&#x2013;91. doi: 10.1016/j.brainres.2018.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.02.018</ArticleId><ArticleId IdType="pmc">PMC5997521</ArticleId><ArticleId IdType="pubmed">29462608</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL, Wilkins OG, Keuss MJ, Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603:124&#x2013;130. doi: 10.1038/s41586-022-04424-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="pubmed">35197626</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Khalil B, Smith CL, Rossoll W. Traffic jam at the nuclear pore: all roads lead to nucleocytoplasmic transport defects in ALS/FTD. Neurobiol Dis. 2020;140:104835. doi: 10.1016/j.nbd.2020.104835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104835</ArticleId><ArticleId IdType="pmc">PMC7253339</ArticleId><ArticleId IdType="pubmed">32179176</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, et al. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133:1763&#x2013;1771. doi: 10.1093/brain/awq111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq111</ArticleId><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Kim HJ, Wang H, Monaghan J, Freyermuth F, Sung JC, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692 e620. doi: 10.1016/j.cell.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.002</ArticleId><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T, Ali R, Jiou J, Fung HYJ, Burke KA, Kim SJ, et al. Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018;173:693&#x2013;705 e622. doi: 10.1016/j.cell.2018.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.003</ArticleId><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M, Hutten S, Bourgeois B, Spreitzer E, Niedner-Boblenz A, Schifferer M, et al. Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell. 2018;173:706&#x2013;719 e713. doi: 10.1016/j.cell.2018.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.004</ArticleId><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S, Wang G, Randle SJ, Ruggeri FS, Varela JA, Lin JQ, et al. FUS phase separation is modulated by a molecular chaperone and methylation of arginine Cation-pi interactions. Cell. 2018;173:720&#x2013;734 e715. doi: 10.1016/j.cell.2018.03.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.056</ArticleId><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Cleveland DW. Rethinking ALS: the FUS about TDP-43. Cell. 2009;136:1001&#x2013;1004. doi: 10.1016/j.cell.2009.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2009.03.006</ArticleId><ArticleId IdType="pmc">PMC3110083</ArticleId><ArticleId IdType="pubmed">19303844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224:213&#x2013;232. doi: 10.1111/j.1365-2818.2006.01706.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2818.2006.01706.x</ArticleId><ArticleId IdType="pubmed">17210054</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi HA, Yoshimura SH. Interactions between non-structured domains of FG- and non-FG-nucleoporins coordinate the ordered assembly of the nuclear pore complex in mitosis. FASEB J. 2020;34:1532&#x2013;1545. doi: 10.1096/fj.201901669R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201901669R</ArticleId><ArticleId IdType="pubmed">31914646</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci. 2010;30:7729&#x2013;7739. doi: 10.1523/JNEUROSCI.5894-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5894-09.2010</ArticleId><ArticleId IdType="pmc">PMC2890254</ArticleId><ArticleId IdType="pubmed">20519548</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Funez P, Sanchez-Garcia J, de Mena L, Zhang Y, Levites Y, Khare S, et al. Holdase activity of secreted Hsp70 masks amyloid-beta42 neurotoxicity in Drosophila. Proc Natl Acad Sci U S A. 2016;113:E5212&#x2013;E5221. doi: 10.1073/pnas.1608045113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1608045113</ArticleId><ArticleId IdType="pmc">PMC5024614</ArticleId><ArticleId IdType="pubmed">27531960</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh MD, Jensen M, Lasser M, Huber E, Yusuff T, Pizzo L, et al. NCBP2 modulates neurodevelopmental defects of the 3q29 deletion in Drosophila and Xenopus laevis models. PLoS Genet. 2020;16:e1008590. doi: 10.1371/journal.pgen.1008590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1008590</ArticleId><ArticleId IdType="pmc">PMC7043793</ArticleId><ArticleId IdType="pubmed">32053595</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JS, Nam HJ, Seo M, Han SK, Choi Y, Nam HG, et al. OASIS: online application for the survival analysis of lifespan assays performed in aging research. PLoS One. 2011;6:e23525. doi: 10.1371/journal.pone.0023525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023525</ArticleId><ArticleId IdType="pmc">PMC3156233</ArticleId><ArticleId IdType="pubmed">21858155</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Kula-Eversole E, Iwanaszko M, Hutchison AL, Dinner A, Allada R. Circadian clocks function in concert with heat shock organizing protein to modulate mutant Huntingtin aggregation and toxicity. Cell Rep. 2019;27:59&#x2013;70 e54. doi: 10.1016/j.celrep.2019.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.03.015</ArticleId><ArticleId IdType="pmc">PMC7237104</ArticleId><ArticleId IdType="pubmed">30943415</ArticleId></ArticleIdList></Reference><Reference><Citation>Croft CL, Cruz PE, Ryu DH, Ceballos-Diaz C, Strang KH, Woody BM, et al. rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies. J Exp Med. 2019;216:539&#x2013;555. doi: 10.1084/jem.20182184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182184</ArticleId><ArticleId IdType="pmc">PMC6400529</ArticleId><ArticleId IdType="pubmed">30770411</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173:182&#x2013;194. doi: 10.2353/ajpath.2008.080003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080003</ArticleId><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 Proteinopathies. J Biol Chem. 2009;284:8516&#x2013;8524. doi: 10.1074/jbc.M809462200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M809462200</ArticleId><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Alexeeva OM, Yamada S, Pribadi A, Zhang Y, Mo B, et al. PABPN1 suppresses TDP-43 toxicity in ALS disease models. Hum Mol Genet. 2015;24:5154&#x2013;5173. doi: 10.1093/hmg/ddv238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv238</ArticleId><ArticleId IdType="pmc">PMC4550816</ArticleId><ArticleId IdType="pubmed">26130692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura SH, Hirano T. HEAT repeats - versatile arrays of amphiphilic helices working in crowded environments? J Cell Sci. 2016;129:3963&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pubmed">27802131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi NC, Adam SA. Functional domains in nuclear import factor p97 for binding the nuclear localization sequence receptor and the nuclear pore. Mol Biol Cell. 1997;8:945&#x2013;956. doi: 10.1091/mbc.8.6.945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.8.6.945</ArticleId><ArticleId IdType="pmc">PMC305705</ArticleId><ArticleId IdType="pubmed">9201707</ArticleId></ArticleIdList></Reference><Reference><Citation>Percipalle P, Clarkson WD, Kent HM, Rhodes D, Stewart M. Molecular interactions between the importin alpha/beta heterodimer and proteins involved in vertebrate nuclear protein import. J Mol Biol. 1997;266:722&#x2013;732. doi: 10.1006/jmbi.1996.0801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1996.0801</ArticleId><ArticleId IdType="pubmed">9102465</ArticleId></ArticleIdList></Reference><Reference><Citation>Cingolani G, Petosa C, Weis K, Muller CW. Structure of importin-beta bound to the IBB domain of importin-alpha. Nature. 1999;399:221&#x2013;229. doi: 10.1038/20367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/20367</ArticleId><ArticleId IdType="pubmed">10353244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednenko J, Cingolani G, Gerace L. Importin beta contains a COOH-terminal nucleoporin binding region important for nuclear transport. J Cell Biol. 2003;162:391&#x2013;401. doi: 10.1083/jcb.200303085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200303085</ArticleId><ArticleId IdType="pmc">PMC2172684</ArticleId><ArticleId IdType="pubmed">12885761</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka S, Iwasaka S, Yoneda Y, Takeyasu K, Yoshimura SH. Individual binding pockets of importin-beta for FG-nucleoporins have different binding properties and different sensitivities to RanGTP. Proc Natl Acad Sci U S A. 2008;105:16101&#x2013;16106. doi: 10.1073/pnas.0802647105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0802647105</ArticleId><ArticleId IdType="pmc">PMC2570979</ArticleId><ArticleId IdType="pubmed">18845677</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM, et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener. 2019;14:9. doi: 10.1186/s13024-019-0310-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-019-0310-z</ArticleId><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Wu Y, Odeh HM, Gendron TF, Jansen-West K, Del Rosso G, et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med. 2020;12:eabb3774. doi: 10.1126/scitranslmed.abb3774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb3774</ArticleId><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S, Stauffer JE, Jiang J, Garcia SD, Taylor AE, Schulte D, et al. Sense-encoded poly-GR dipeptide repeat proteins correlate to neurodegeneration and uniquely co-localize with TDP-43 in dendrites of repeat-expanded C9orf72 amyotrophic lateral sclerosis. Acta Neuropathol 2018;135:459&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935138</ArticleId><ArticleId IdType="pubmed">29196813</ArticleId></ArticleIdList></Reference><Reference><Citation>Weskamp K, Tank EM, Miguez R, McBride JP, Gomez NB, White M, et al. Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS. J Clin Invest. 2020;130:1139&#x2013;1155. doi: 10.1172/JCI130988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI130988</ArticleId><ArticleId IdType="pmc">PMC7269575</ArticleId><ArticleId IdType="pubmed">31714900</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601:139&#x2013;143. doi: 10.1038/s41586-021-04199-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId><ArticleId IdType="pmc">PMC7612255</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, et al. Cytoplasmic TDP-43 De-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102:339&#x2013;357 e337. doi: 10.1016/j.neuron.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Barreau A, Rohatgi R. Phase separation-deficient TDP43 remains functional in splicing. Nat Commun. 2019;10:4890. doi: 10.1038/s41467-019-12740-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12740-2</ArticleId><ArticleId IdType="pmc">PMC6814767</ArticleId><ArticleId IdType="pubmed">31653829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippai M, Tirian L, Boros I, Mihaly J, Erdelyi M, Belecz I, et al. The Ketel gene encodes a Drosophila homologue of importin-beta. Genetics. 2000;156:1889&#x2013;1900. doi: 10.1093/genetics/156.4.1889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/genetics/156.4.1889</ArticleId><ArticleId IdType="pmc">PMC1461400</ArticleId><ArticleId IdType="pubmed">11102382</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin MS, Croft CL, Futch HS, Ryu D, Ceballos-Diaz C, Liu X, et al. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Mol Neurodegener. 2020;15:15. doi: 10.1186/s13024-020-00361-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00361-z</ArticleId><ArticleId IdType="pmc">PMC7053119</ArticleId><ArticleId IdType="pubmed">32122372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita Y, Ito H, Hirano A, Fujita K, Wate R, Nakamura M, et al. Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2009;68:1184&#x2013;1192. doi: 10.1097/NEN.0b013e3181bc3bec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181bc3bec</ArticleId><ArticleId IdType="pubmed">19816199</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagara Y, Tateishi T, Yamasaki R, Hayashi S, Kawamura M, Kikuchi H, et al. Impaired cytoplasmic-nuclear transport of hypoxia-inducible factor-1alpha in amyotrophic lateral sclerosis. Brain Pathol. 2013;23:534&#x2013;546. doi: 10.1111/bpa.12040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12040</ArticleId><ArticleId IdType="pmc">PMC8029229</ArticleId><ArticleId IdType="pubmed">23368766</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H, Yamashita T, Kato H, Kimura T, Kwak S. Impaired Nucleoporins are present in sporadic amyotrophic lateral sclerosis motor neurons that exhibit Mislocalization of the 43-kDa TAR DNA-binding protein. J Clin Neurol. 2019;15:62&#x2013;67. doi: 10.3988/jcn.2019.15.1.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2019.15.1.62</ArticleId><ArticleId IdType="pmc">PMC6325357</ArticleId><ArticleId IdType="pubmed">30618218</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Aizawa H, Teramoto S, Akamatsu M, Kwak S. Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons. Sci Rep. 2017;7:39994. doi: 10.1038/srep39994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep39994</ArticleId><ArticleId IdType="pmc">PMC5206745</ArticleId><ArticleId IdType="pubmed">28045133</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, MacNair L, McGoldrick P, McKeever PM, McLean JR, Zhang M, et al. Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann Neurol. 2015;78:568&#x2013;583. doi: 10.1002/ana.24469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24469</ArticleId><ArticleId IdType="pubmed">26174152</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson EN, Morera AA, Kour S, Cherry JD, Ramesh N, Gleixner A, et al. Traumatic injury compromises nucleocytoplasmic transport and leads to TDP-43 pathology. Elife. 2021;10:e67587. doi: 10.7554/eLife.67587.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.67587</ArticleId><ArticleId IdType="pmc">PMC8169113</ArticleId><ArticleId IdType="pubmed">34060470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gleixner AM, Verdone BM, Otte CG, Anderson EN, Ramesh N, Shapiro OR, et al. NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. Nat Commun. 2022;13:3380. doi: 10.1038/s41467-022-31098-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31098-6</ArticleId><ArticleId IdType="pmc">PMC9192689</ArticleId><ArticleId IdType="pubmed">35697676</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) Acta Neuropathol. 2014;127:423&#x2013;439. doi: 10.1007/s00401-013-1238-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Tredici KD, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating SS, San Gil R, Swanson MEV, Scotter EL, Walker AK. TDP-43 pathology: from noxious assembly to therapeutic removal. Prog Neurobiol. 2022;211:102229.</Citation><ArticleIdList><ArticleId IdType="pubmed">35101542</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey JL, Guo L. Liquid-liquid phase separation of TDP-43 and FUS in physiology and pathology of neurodegenerative diseases. Front Mol Biosci. 2022;9:826719. doi: 10.3389/fmolb.2022.826719.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.826719</ArticleId><ArticleId IdType="pmc">PMC8847598</ArticleId><ArticleId IdType="pubmed">35187086</ArticleId></ArticleIdList></Reference><Reference><Citation>Springhower CE, Rosen MK, Chook YM. Karyopherins and condensates. Curr Opin Cell Biol. 2020;64:112&#x2013;123. doi: 10.1016/j.ceb.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7371519</ArticleId><ArticleId IdType="pubmed">32474299</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Nogales M, Lucas JJ. Altered levels and isoforms of tau and nuclear membrane invaginations in Huntington's disease. Front Cell Neurosci. 2019;13:574. doi: 10.3389/fncel.2019.00574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00574</ArticleId><ArticleId IdType="pmc">PMC6978886</ArticleId><ArticleId IdType="pubmed">32009905</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, et al. Tau protein disrupts Nucleocytoplasmic transport in Alzheimer's disease. Neuron. 2019;101:349. doi: 10.1016/j.neuron.2018.12.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.12.031</ArticleId><ArticleId IdType="pmc">PMC6377243</ArticleId><ArticleId IdType="pubmed">30653936</ArticleId></ArticleIdList></Reference><Reference><Citation>Paonessa F, Evans LD, Solanki R, Larrieu D, Wray S, Hardy J, et al. Microtubules deform the nuclear membrane and disrupt Nucleocytoplasmic transport in tau-mediated Frontotemporal dementia. Cell Rep. 2019;26:582&#x2013;593 e585. doi: 10.1016/j.celrep.2018.12.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.12.085</ArticleId><ArticleId IdType="pmc">PMC6335264</ArticleId><ArticleId IdType="pubmed">30650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelison GL, Levy SA, Jenson T, Frost B. Tau-induced nuclear envelope invagination causes a toxic accumulation of mRNA in Drosophila. Aging Cell. 2019;18:e12847. doi: 10.1111/acel.12847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12847</ArticleId><ArticleId IdType="pmc">PMC6351838</ArticleId><ArticleId IdType="pubmed">30411463</ArticleId></ArticleIdList></Reference><Reference><Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, et al. Tau protein disrupts Nucleocytoplasmic transport in Alzheimer's disease. Neuron. 2018;99:925&#x2013;940 e927. doi: 10.1016/j.neuron.2018.07.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.07.039</ArticleId><ArticleId IdType="pmc">PMC6240334</ArticleId><ArticleId IdType="pubmed">30189209</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, Atwal RS, Artates JW, Tabet R, et al. Polyglutamine-expanded Huntingtin exacerbates age-related disruption of nuclear integrity and Nucleocytoplasmic transport. Neuron. 2017;94:48&#x2013;57 e44. doi: 10.1016/j.neuron.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5479704</ArticleId><ArticleId IdType="pubmed">28384474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shani V, Safory H, Szargel R, Wang N, Cohen T, Elghani FA, et al. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. Hum Mol Genet. 2019;28:3982&#x2013;3996. doi: 10.1093/hmg/ddz245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz245</ArticleId><ArticleId IdType="pmc">PMC7335485</ArticleId><ArticleId IdType="pubmed">31626293</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling AL, Shorter J. Combating deleterious phase transitions in neurodegenerative disease. Biochim Biophys Acta, Mol Cell Res. 2021;1868:118984. doi: 10.1016/j.bbamcr.2021.118984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2021.118984</ArticleId><ArticleId IdType="pmc">PMC7965345</ArticleId><ArticleId IdType="pubmed">33549703</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Fare CM, Shorter J. Therapeutic dissolution of aberrant phases by nuclear-import receptors. Trends Cell Biol. 2019;29:308&#x2013;322. doi: 10.1016/j.tcb.2018.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2018.12.004</ArticleId><ArticleId IdType="pmc">PMC6750949</ArticleId><ArticleId IdType="pubmed">30660504</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutten S, Usluer S, Bourgeois B, Simonetti F, Odeh HM, Fare CM, et al. Nuclear import receptors directly bind to arginine-rich dipeptide repeat proteins and suppress their pathological interactions. Cell Rep. 2020;33:108538. doi: 10.1016/j.celrep.2020.108538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108538</ArticleId><ArticleId IdType="pmc">PMC7814465</ArticleId><ArticleId IdType="pubmed">33357437</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll SG, Cingolani G. Importin alpha/beta and the tug of war to keep TDP-43 in solution: quo vadis? Bioessays. 2022;44:e2200181.</Citation><ArticleIdList><ArticleId IdType="pubmed">36253101</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll SG, Meshkin H, Bryer AJ, Li F, Ko YH, Lokareddy RK, et al. Recognition of the TDP-43 nuclear localization signal by importin alpha1/beta. Cell Rep. 2022;39:111007. doi: 10.1016/j.celrep.2022.111007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111007</ArticleId><ArticleId IdType="pmc">PMC9290431</ArticleId><ArticleId IdType="pubmed">35767952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez A, Mannen T, Cagatay T, Fujiwara A, Matsumura H, Niesman AB, et al. Mechanism of karyopherin-beta2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X) Sci Rep. 2021;11:3754. doi: 10.1038/s41598-021-83196-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-83196-y</ArticleId><ArticleId IdType="pmc">PMC7881136</ArticleId><ArticleId IdType="pubmed">33580145</ArticleId></ArticleIdList></Reference><Reference><Citation>Baade I, Hutten S, Sternburg EL, Porschke M, Hofweber M, Dormann D, et al. The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors. J Biol Chem. 2021;296:100659. doi: 10.1016/j.jbc.2021.100659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100659</ArticleId><ArticleId IdType="pmc">PMC8131929</ArticleId><ArticleId IdType="pubmed">33857479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YC, Kumar MS, Ramesh N, Anderson EN, Nguyen AT, Kim B, et al. Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nat Neurosci. 2021;24:1077&#x2013;1088. doi: 10.1038/s41593-021-00859-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00859-9</ArticleId><ArticleId IdType="pmc">PMC8832378</ArticleId><ArticleId IdType="pubmed">34059832</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Gorlich D. Transport selectivity of nuclear pores, phase separation, and Membraneless organelles. Trends Biochem Sci. 2016;41:46&#x2013;61. doi: 10.1016/j.tibs.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2015.11.001</ArticleId><ArticleId IdType="pubmed">26705895</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakel S, Mingot JM, Schwarzmaier P, Hartmann E, Gorlich D. Importins fulfil a dual function as nuclear import receptors and cytoplasmic chaperones for exposed basic domains. EMBO J. 2002;21:377&#x2013;386. doi: 10.1093/emboj/21.3.377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/21.3.377</ArticleId><ArticleId IdType="pmc">PMC125346</ArticleId><ArticleId IdType="pubmed">11823430</ArticleId></ArticleIdList></Reference><Reference><Citation>Padavannil A, Sarkar P, Kim SJ, Cagatay T, Jiou J, Brautigam CA, et al. Importin-9 wraps around the H2A-H2B core to act as nuclear importer and histone chaperone. Elife. 2019;8:e43630. doi: 10.7554/eLife.43630.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.43630</ArticleId><ArticleId IdType="pmc">PMC6453568</ArticleId><ArticleId IdType="pubmed">30855230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang A, Eriksson J, Schink KO, Lang E, Blicher P, Polec A, et al. Visualization of PML nuclear import complexes reveals FG-repeat nucleoporins at cargo retrieval sites. Nucleus. 2017;8:404&#x2013;420. doi: 10.1080/19491034.2017.1306161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19491034.2017.1306161</ArticleId><ArticleId IdType="pmc">PMC5597291</ArticleId><ArticleId IdType="pubmed">28402725</ArticleId></ArticleIdList></Reference><Reference><Citation>Milles S, Huy Bui K, Koehler C, Eltsov M, Beck M, Lemke EA. Facilitated aggregation of FG nucleoporins under molecular crowding conditions. EMBO Rep. 2013;14:178&#x2013;183. doi: 10.1038/embor.2012.204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2012.204</ArticleId><ArticleId IdType="pmc">PMC3596131</ArticleId><ArticleId IdType="pubmed">23238392</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Van Deerlin VM, Kwong LK, Yuan W, Wood EM, Yu CE, et al. A90V TDP-43 variant results in the aberrant localization of TDP-43 in vitro. FEBS Lett. 2008;582:2252&#x2013;2256. doi: 10.1016/j.febslet.2008.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.05.024</ArticleId><ArticleId IdType="pmc">PMC2478749</ArticleId><ArticleId IdType="pubmed">18505686</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Wesolowski SS, Chadchankar J, Delsing L, Jacobsen S, Mukherjee J, et al. Cytoplasmic Relocalization of TAR DNA-binding protein 43 is not sufficient to reproduce cellular pathologies associated with ALS in vitro. Front Mol Neurosci. 2017;10:46. doi: 10.3389/fnmol.2017.00046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00046</ArticleId><ArticleId IdType="pmc">PMC5323424</ArticleId><ArticleId IdType="pubmed">28286471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Duan L, Bowen K, Kalab P, Rothstein JD. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. Elife. 2020;9:e51685. doi: 10.7554/eLife.51685.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.51685</ArticleId><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Krach F, Batra R, Wheeler EC, Vu AQ, Wang R, Hutt K, et al. Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol. 2018;136:405&#x2013;423. doi: 10.1007/s00401-018-1870-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1870-7</ArticleId><ArticleId IdType="pmc">PMC6215775</ArticleId><ArticleId IdType="pubmed">29881994</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeh HM, Fare CM, Shorter J. Nuclear-import receptors counter deleterious phase transitions in neurodegenerative disease. J Mol Biol. 2022;434:167220. doi: 10.1016/j.jmb.2021.167220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167220</ArticleId><ArticleId IdType="pmc">PMC8748273</ArticleId><ArticleId IdType="pubmed">34464655</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>